Auransa Inc.

Sct Ii LLC

Sct Incorporated

Ayasdi Ai LLC

Ayasdi, Inc.

Pek Yee Lum

Sidney Paul Elmer

Joseph C Wu

Zhong Zhong

Christopher G Armstrong

Guanyi Huang

Lisa Maria Lucia Pham

Kevin J Kim

Viwat Visuthikraisee

Eithon Michael G Cadag

Thomas Bernard Freeman

Eunhye Park

Harlan Sexton

Andrew Asher Protter

Joshua Lewis

Hak Jin Chang

Eithon Cadag

Johan Grahnen

Sarvajit Chakravarty

Michael J Green

Son Minh Pham

Gregory R Luedtke

Anna Halberg

Rajaa Sukhun

Christopher Armour

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Analogues of pentamidine and uses therefor

This disclosure provides genomics-based methods that can be used to identify, quantify, and characterize rare cell types, including circulating tumor cells.

Genomics-based identification and characterization of rare cell types

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3',4&#x2032;,5&#x2032;-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer.

Derivatives of piperlongumine and uses thereof

An example method comprises receiving historical information of episodes, constructing event sets from the historical information, categorizing each event with general labels and synthetic labels, learning an event metric on the events by using the general and synthetic labels to perform dimensionality reduction to associate a vector with each event and to determine an angle between every two vectors, determining an event set metric using distances between each pair of event sets, deriving a sequence metric on the episodes, the sequence metric obtaining a preferred match between two episodes, deriving a subsequence metric on the episodes, the subsequence metric is a function of the event set metric on subsequences of each episode, grouping episodes into subgroups based on distances, for at least one subgroup, generating a consensus sequence by finding a preferred sequence of events, and the episodes of the subgroup, and generating a report indicating the consensus sequence.

Consensus sequence identification

Growing community of inventors

Palo Alto, CA, United States of America

Pek Yee Lum